https://www.selleckchem.com/products/LBH-589.html
The management of Graves' disease (GD) in the US is shifting towards increased use of anti-thyroid drugs (ATD). If patients fail to achieve remission after a standard course of therapy of 12-18months, long-term treatment with ATD (≥24months) may be chosen over definitive therapy with radioiodine (RAI) or surgery. Clinicians will need to contrast this strategy to ablative therapies as they help patients in decision making. Review of the literature illustrates that long-term ATD delivers euthyroidism with minimal complications, low financ
Like
Comment
Share
